Stock EVH EVOLENT HEALTH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Evolent Health, Inc.

Equities

EVH

US30050B1017

Advanced Medical Equipment & Technology

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-26 pm EDT 		5-day change 1st Jan Change
27.65 USD -2.37% Intraday chart for Evolent Health, Inc. -6.30% -16.29%
Apr. 22 Citigroup Starts Coverage on Evolent Health With Buy Rating, $40 Price Target MT
Mar. 28 Canaccord Genuity Trims Price Target on Evolent Health to $44 From $45, Maintains Buy Rating MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 759.3 1,351 2,431 2,798 3,797 3,149 - -
Enterprise Value (EV) 1 950.2 1,297 2,431 3,023 4,201 3,540 3,421 3,219
P/E ratio -2.47 x -4.07 x -62.9 x -140 x -25.8 x 1,199 x 57.4 x 26.6 x
Yield - - - - - 0.97% 0.91% 0.86%
Capitalization / Revenue 0.9 x 1.32 x 2.68 x 2.07 x 1.93 x 1.28 x 1.1 x 0.95 x
EV / Revenue 1.12 x 1.27 x 2.68 x 2.24 x 2.14 x 1.43 x 1.2 x 0.97 x
EV / EBITDA -86.6 x 31.3 x 36.7 x 28.4 x 21.6 x 14 x 10.5 x 8.08 x
EV / FCF -12.2 x -28.4 x 177 x -60.6 x 36.9 x 24.7 x 14.3 x 10.6 x
FCF Yield -8.23% -3.52% 0.57% -1.65% 2.71% 4.05% 7.01% 9.39%
Price to Book 0.83 x - - - 3.44 x 2.61 x 2.64 x 2.63 x
Nbr of stocks (in thousands) 83,904 84,310 87,873 99,653 114,960 113,893 - -
Reference price 2 9.050 16.03 27.67 28.08 33.03 27.65 27.65 27.65
Announcement Date 2/25/20 2/25/21 2/23/22 2/22/23 2/22/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 846.4 1,022 908 1,352 1,964 2,467 2,862 3,303
EBITDA 1 -10.97 41.44 66.32 106.3 194.7 252.7 325 398.4
EBIT 1 -47.4 3.937 26.81 59.98 146.1 184.9 254.7 326.7
Operating Margin -5.6% 0.39% 2.95% 4.44% 7.44% 7.49% 8.9% 9.89%
Earnings before Tax (EBT) 1 -327.1 -337.8 -29.8 -62.08 -202.4 47.27 116 187.6
Net income 1 -302 -334.2 -37.6 -18.7 -142.3 19.91 69.47 143.7
Net margin -35.68% -32.69% -4.14% -1.38% -7.24% 0.81% 2.43% 4.35%
EPS 2 -3.670 -3.940 -0.4400 -0.2000 -1.280 0.0231 0.4815 1.040
Free Cash Flow 1 -78.18 -45.7 13.76 -49.91 113.8 143.4 239.9 302.3
FCF margin -9.24% -4.47% 1.52% -3.69% 5.8% 5.81% 8.38% 9.15%
FCF Conversion (EBITDA) - - 20.75% - 58.47% 56.73% 73.83% 75.87%
FCF Conversion (Net income) - - - - - 720.16% 345.36% 210.31%
Dividend per Share 2 - - - - - 0.2693 0.2523 0.2373
Announcement Date 2/25/20 2/25/21 2/23/22 2/22/23 2/22/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 222.5 248.4 297.1 319.9 352.6 382.4 427.7 469.1 511 556.1 598.9 606.6 622 636.7 692.8
EBITDA 1 13.76 24.3 24.26 21.74 28.06 32.28 50.5 47.41 48.71 48.06 54.71 59.8 64.76 73.38 74.21
EBIT 1 4.027 12.76 13.72 11.19 17.7 17.37 33.97 36.59 46.73 35.77 36.73 42.98 46.57 55.85 56.05
Operating Margin 1.81% 5.14% 4.62% 3.5% 5.02% 4.54% 7.94% 7.8% 9.14% 6.43% 6.13% 7.08% 7.49% 8.77% 8.09%
Earnings before Tax (EBT) 1 -12.81 2.6 -4.148 -4.309 -43.39 -10.23 -88.17 -35.29 -30.87 -48.07 3.816 7.313 14.77 21.4 22.56
Net income 1 -13.04 -5.647 -5.35 -4.588 2.123 -11.35 -26.26 -41.41 -33.2 -41.4 -0.3668 2.88 8.523 14.67 12
Net margin -5.86% -2.27% -1.8% -1.43% 0.6% -2.97% -6.14% -8.83% -6.5% -7.44% -0.06% 0.47% 1.37% 2.3% 1.73%
EPS 2 -0.1500 -0.0600 -0.0600 -0.0500 0.0200 -0.1100 -0.2400 -0.3700 -0.3000 -0.3600 -0.1333 -0.0241 0.0523 0.1417 0.1175
Dividend per Share 2 - - - - - - - - - - 0.0691 0.0679 0.0668 0.0657 0.0646
Announcement Date 11/3/21 2/23/22 5/4/22 8/2/22 11/2/22 2/22/23 5/3/23 8/2/23 11/2/23 2/22/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 191 - - 225 404 391 272 69.8
Net Cash position 1 - 54.4 - - - - - -
Leverage (Debt/EBITDA) -17.4 x - - 2.114 x 2.076 x 1.546 x 0.8357 x 0.1753 x
Free Cash Flow 1 -78.2 -45.7 13.8 -49.9 114 143 240 302
ROE (net income / shareholders' equity) -5.83% - -5.73% 11.5% 10.1% 11.7% 15% 17.1%
ROA (Net income/ Total Assets) -3.74% - - 5.51% 4.32% 3.57% 4.98% 6.57%
Assets 1 8,072 - - -339.5 -3,293 558.4 1,395 2,187
Book Value Per Share 2 10.90 - - - 9.600 10.60 10.50 10.50
Cash Flow per Share - - - - - - - -
Capex 1 35.5 29.5 25 38.4 28.7 32.5 37.8 40.3
Capex / Sales 4.2% 2.88% 2.75% 2.84% 1.46% 1.32% 1.32% 1.22%
Announcement Date 2/25/20 2/25/21 2/23/22 2/22/23 2/22/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Evolent Health, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
27.65 USD
Average target price
44.86 USD
Spread / Average Target
+62.23%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Software & Technology Services

1st Jan change Capi.
EVOLENT HEALTH, INC. Stock Evolent Health, Inc.
-16.29% 3.15B
VEEVA SYSTEMS INC. Stock Veeva Systems Inc.
+4.36% 32.47B
PRO MEDICUS LIMITED Stock Pro Medicus Limited
+14.14% 7.45B
SECTRA AB Stock Sectra AB
+22.93% 3.89B
OMNICELL, INC. Stock Omnicell, Inc.
-25.96% 1.28B
LUNIT INC. Stock Lunit Inc.
-36.14% 1.09B
SIMULATIONS PLUS, INC. Stock Simulations Plus, Inc.
-0.13% 893M
B-SOFT CO.,LTD. Stock B-SOFT Co.,Ltd.
-35.42% 902M
VERADIGM INC. Stock Veradigm Inc.
-24.12% 857M
SURGICAL SCIENCE SWEDEN AB Stock Surgical Science Sweden AB
-18.47% 693M
Medical Software & Technology Services
  1. Stock Market
  2. Equities
  3. EVH Stock
  4. Financials Evolent Health, Inc.